FDA Breakthrough Device designation vs clearance or approval
Breakthrough Device designation gives an eligible device prioritized FDA interaction during development; it is not permission to market. A designated device still needs the applicable 510(k) clearance, De Novo grant, or PMA approval for its exact intended use. Verify both records and their dates.
FDA Breakthrough Device designation is not clearance, approval, or permission to sell a device. It gives an eligible device access to prioritized FDA interaction and review tools during development. Before a commercial use is represented as authorized, the exact device still needs the applicable 510(k) clearance, De Novo grant, or PMA approval for the exact intended use.12
The program name is easy to overread because “breakthrough” sounds like an outcome judgment. It describes eligibility and process, not a finding that the device works better than alternatives.
Put designation and authorization on separate lines
| Record | What it can establish | What it cannot establish |
|---|---|---|
| Breakthrough designation | FDA accepted the device into the program based on statutory criteria and the information available at that stage | Marketing permission, final safety and effectiveness determination, superiority, or coverage |
| 510(k) clearance | FDA found the exact device substantially equivalent to a legally marketed predicate for stated uses | PMA approval or every use in an advertisement |
| De Novo grant | FDA created a classification and authorized a novel low- or moderate-risk device for stated uses | A universal category endorsement or later model changes |
| PMA approval | FDA approved a specific higher-risk device application for labeled uses after its review standard | A clinic, operator, off-label use, or guaranteed outcome |
| Study registration or IDE | A clinical investigation record or permission framework may exist | Commercial marketing authorization |
Search the manufacturer and proprietary device name in FDA databases. Preserve model, submission number, decision date, product code, regulation number, indication or intended use, labeling, and supplements.3 A press release may mention designation but omit that no marketing decision has occurred.
The statutory criteria are important but bounded
FDA explains that the program is for certain devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions and meet another statutory criterion, such as representing breakthrough technology or offering a significant advantage over existing alternatives.12 The determination is based on the program request and development-stage evidence.
Do not rewrite that as “FDA determined it is clinically superior.” The later premarket submission has its own evidence, review standard, indication, and decision. A device can hold designation while still being investigated, revised, delayed, or never authorized for marketing.
Public totals show why the stages matter
FDA publishes cumulative counts of designations and later marketing authorizations. Through June 30, 2026, the agency’s page reported 1,320 Breakthrough Device designations and 210 marketing authorizations.1 The difference does not mean the remaining devices failed. It shows that designation and authorization are separate milestones and that many designated devices have not reached a public marketing authorization.
FDA generally treats designation requests as confidential unless the sponsor discloses them. A company announcement should therefore identify the device and date precisely. Ask whether FDA itself has published the later authorization record.
Match the commercial claim to the authorized indication
Even after authorization, compare the clinic’s claim with the wording in the FDA decision and labeling:
- disease, condition, or aesthetic target;
- diagnostic, monitoring, screening, treatment, or adjunctive role;
- population and age range;
- body site, sample, route, and setting;
- prescription or over-the-counter status;
- operator training and contraindications; and
- device model, accessories, software version, and required follow-up.
“Uses breakthrough technology” may also be ordinary marketing language rather than a claim of FDA designation. Ask the seller to state which meaning it intends.
Create a two-document evidence packet
The cleanest record includes the sponsor’s dated designation announcement or other reliable designation evidence and the later FDA marketing decision, if one exists. Add current labeling and any safety communications, recalls, or decision supplements. If there is no later authorization, the ad should not imply lawful commercial marketing based on designation alone.
For a clinic procedure, add the facility, operator, training, prescription, consent, device identifier, settings, maintenance, adverse-event, and follow-up records. FDA authorization of a device is not authorization of a provider.
- Identify the exact device. Record manufacturer, proprietary name, model, software, accessories, and claimed Breakthrough designation date.
- Verify designation separately. Read the program claim as a development milestone, preserving criteria and confidentiality limits.
- Find the marketing decision. Locate the applicable 510(k), De Novo, or PMA record and decision date—or document that none was found.
- Match the indication. Compare population, condition, body site, role, setting, operator, and warnings word for word with the commercial use.
- Verify the provider system. Check clinician, facility, device identifier, training, consent, settings, maintenance, complication response, and follow-up.
The decisive regulatory question is: “Where are the separate records for this exact device’s Breakthrough designation and its current marketing authorization, and does the authorized indication match the use being sold?”
Sources
- U.S. Food and Drug Administration. Breakthrough Devices Program. Used for program eligibility, designation, interaction, review-priority, public totals, confidentiality, and marketing-authorization distinctions. Accessed .
- U.S. Food and Drug Administration. Breakthrough Devices Program guidance. Used for current program policy, designation criteria, mechanisms, and the separate premarket review pathway. Accessed .
- U.S. Food and Drug Administration. Learn if a Medical Device Has Been Cleared by FDA for Marketing. Used for consumer verification of 510(k), De Novo, and PMA records and the exact device and intended use. Accessed .